Biopharmaceutical Company Announces Completion of Oral Drug Substance For UC

Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, has recently made a advancement in its drug development program. The Company announced the successful completion of the first Good Manufacturing Practice (GMP) batch of its drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug currently under development for patients affected by ulcerative colitis (UC). $Palisade Bio (PALI.US)$